Making practical markets for vaccines: Why I decided that the Center for Global Development Report, Making Markets for Vaccines, offers poor advice to government and foundation leaders

PLoS Medicine

Volumn 2, Issue 10, 2005, Pages 0934-0938

  Light, Donald W ^a,b  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MALARIA VACCINE; VACCINE;

COST BENEFIT ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; FINANCIAL MANAGEMENT; GOVERNMENT; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; INVESTMENT; PATENT; SHELF LIFE; SHORT SURVEY; ARTICLE; HEALTH; HUMAN; MEDICAL RESEARCH; THEORETICAL MODEL;

BIOMEDICAL RESEARCH; HUMANS; MARKETING OF HEALTH SERVICES; MODELS, THEORETICAL; RESEARCH SUPPORT AS TOPIC; VACCINES; WORLD HEALTH;

EID: 27644453035     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0020271     Document Type: Short Survey

References (17)

1. Center for Global Development (2005) Making markets for vaccines: Ideas into action. Washington (D. C.): Center for Global Development. 115 p.
2. Kremer M (2001) Creating markets for new vaccines: Parts 1 & 2. In: Jaffe AB, Lerner J, Stern S, editors. Innovation policy and the economy. Volume 1. Cambridge (Massachusetts): MIT Press. 300 p.
3. Finkelstein A (2004) Static and dynamic effects of health policy: Evidence from the vaccine industry. Q J Econ 119: 527-564.
4. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, et al. (2004) Efficacy of the RTS,S/ASO2A vaccine against Plasmodium falciparum infection and disease in young African children: Randomized controlled trial. Lancet 364: 1411-1420.
5. Acemoglu D, Linn J (2004) Market size in innovation: Theory and evidence from the pharmaceutical industry. Q J Econ 119: 1049-1090.
6. National Institute for Health Care Management Research and Education Foundation (2002) Changing patterns of pharmaceutical innovation. Washington (D. C.): National Institute for Health Care Management. Available: http://www.nihcm.org/innovations.pdf. Accessed 17 July 2005.
7. Prescrire International (2003) A review of new drugs and indications in 2002: Financial speculation or better patient care? Prescrire Int 12: 74-77.
8. Towse A (2004) The initiative on publicprivate partnerships for health: Estimates of the medium term financial resource needs for development of pharmaceutical to combat neglected diseases. London: Office of Health Economics. 47 p.
9. Moran M (2005) New EU approaches to funding R&D for neglected diseases. Available: http://www.who.int/intellectualproperty/submissions/Mary. Moran.pdf. Accessed 15 July 2005.
10. Kremer M, Glennester R (2004) Strong medicine: Creating incentives for pharmaceutical research on neglected diseases. Princeton (New Jersey): Princeton University Press. 152 p.
11. Farlow A (2004) Over the rainbow: the pot of gold for neglected diseases. Lancet 364: 2011-2012.
12. Farlow A, Light DW, Mahoney RT, Widdus R (2005) Concerns regarding the Center for Global Development report, "Making Markets for Vaccines." Geneva: Commission on Intellectual Property Rights, Innovation and Public Health. Available: http://www.economics.ox.ac.uk/members/andrew.farlow/ CIPIH1May2005.pdf. Accessed 15 July 2005.
13. Barder O, Kremer M, Levine R (2005) Answering concerns about Making Markets for Vaccines. Geneva: Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH). Available: http://www.who.int/ intellectualproperty/submissions/BarderSubmission.pdf. Accessed 15 July 2005.
14. Maurer S (2005) The right tool(s): Designing cost-effective strategies for neglected disease research. Berkeley (California): University of California at Berkeley Goldman School of Public Policy. Available: http://www.who.int/ intellectualproperty/studies/S.Maurer.pdf. Accessed 15 July 2005.
15. G8 Finance Ministers (2005) G8 Finance Ministers' conclusions on development. June. London: HM Treasury. Available: http://www.hm-treasury.gov. uk./otherhmtsites/g7/news/conclusions_on_development_110605.cfm. Accessed 1 August 2005.
16. Gates Foundation (2005) Grand challenges in global health: Gates Foundation, 2005. Available: http://www.grandchallengesgh.org/subcontent.aspx? SecID=408. Accessed 15 July 2005.
17. Birn AE (2005) Gates's grandest challenge: Transcending technology as public health ideology. Available: http://image.thelancet.com/extras/ 04art6429web.pdf. Accessed 15 July 2005.